Iovance Biotherapeutics Inc. Common Stock vs MetLife Inc. Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.5 (market cap $5.85B), while MetLife Inc. Common Stock trades at $98.97 (market cap $60.87B). The key difference: MetLife Inc. Common Stock is far larger — about 10.4× Iovance Biotherapeutics Inc. Common Stock's market cap, and MetLife Inc. Common Stock pays a 2.47% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and MetLife Inc. Common Stock for 0 Days on average.
| IOVA | MET | |
|---|---|---|
Market Cap | $5.85B | $60.87B |
Volume | 14,517,176 | 3,175,937 |
Sector | Health | Financials |
52-Week High | $14.82 | $99.95 |
52-Week Low | $1.81 | $67.70 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.78B | $81.79B |
Dividend Yield | — | 2.47% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →